{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:28:54Z","timestamp":1750480134429},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":8236,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[1984,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria. Although complete regressions remain exceptional, a number of agents, eg, doxorubicin and cisplatin have been shown to be effective in the treatment of this disease. So far, combinations of effective agents with or without concomitant hormone therapy have not proven to be more effective than single agents. Androgen priming has considerable theoretical appeal and deserves further consideration. A higher effectiveness of chemotherapeutic agents might be obtained by linkage to various carriers. Estramustine phosphate is an example of such a complex that has a cytotoxic effect in test systems in which estrogen has no effect and in patients with hormone\u2010refractory prostatic cancer. The use of hormonal and other carriers that could increase the specificity of chemotherapeutic agents deserves extensive exploration.<\/jats:p>","DOI":"10.1002\/pros.2990050106","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T00:08:48Z","timestamp":1172016528000},"page":"55-62","source":"Crossref","is-referenced-by-count":10,"title":["Chemotherapy principles in the treatment of prostatic cancer"],"prefix":"10.1002","volume":"5","author":[{"given":"I.","family":"K\u00f6nyves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"M\u00fcntzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rozencweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197311)32:5<1131::AID-CNCR2820320519>3.0.CO;2-N"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)56140-6"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-5-681"},{"key":"e_1_2_1_5_2","first-page":"321","volume-title":"Prostate Cancer","author":"Pavone\u2010Macaluso M","year":"1982"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197911)44:5<1553::AID-CNCR2820440502>3.0.CO;2-W"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0"},{"key":"e_1_2_1_8_2","first-page":"325","article-title":"Comparative trial of adriamycin and 5\u2010fluorouracil in advanced prostatic cancer\u2014Progress report","volume":"61","author":"DeWys WD","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53866-5"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)54961-7"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800315)45:6<1300::AID-CNCR2820450606>3.0.CO;2-0"},{"key":"e_1_2_1_12_2","first-page":"999","article-title":"Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: A phase II study","volume":"63","author":"Izbicki RM","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)59077-1"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801201)46:11<2389::AID-CNCR2820461114>3.0.CO;2-T"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0022-5347(17)56538-6","article-title":"Cyclophosphamide, doxorubicin hydrochloride and 5\u2010fluorouracil in advanced carcinoma of the prostate","volume":"122","author":"Soloway MS","year":"1979","journal-title":"J Urol"},{"key":"e_1_2_1_16_2","first-page":"115","article-title":"Treatment of advanced prostate cancer with cyclophosphamide (C), adriamycin (A) and methotrexate (M)","volume":"23","author":"Straus MJ","year":"1982","journal-title":"Proc AACR\/ASCO"},{"key":"e_1_2_1_17_2","first-page":"1579","article-title":"Treatment of genitourinary tumors with cis\u2010dichlorodiammineplatinum (II): Experience in 250 patients","volume":"63","author":"Merrin CE","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(80)90401-X"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254047"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)67048-4"},{"key":"e_1_2_1_21_2","first-page":"325","article-title":"Multiagent chemotherapy in advanced prostatic cancer\u2014Measurement of responsiveness","volume":"19","author":"Paulson D","year":"1978","journal-title":"Proc AACR\/ASCO"},{"key":"e_1_2_1_22_2","first-page":"1403","article-title":"Cisplatin, cyclophosphamide and prednisone therapy for stage D prostatic cancer","volume":"66","author":"Berry J","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00256893"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(77)90131-5"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-99-6-1501"},{"key":"e_1_2_1_26_2","first-page":"2339","article-title":"Proliferation kinetics of human breast cancer cell line in vitro following treatment with 17\u03b2\u2010estradiol and 1\u2010\u03b2\u2010D\u2010arabinofuranosylcytosine","volume":"38","author":"Weichselbaum RR","year":"1978","journal-title":"Cancer Res"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108839"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198301203080304"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821001)50:7<1332::AID-CNCR2820500719>3.0.CO;2-8"},{"key":"e_1_2_1_30_2","first-page":"98","article-title":"The steroid molecule as a carrier of cytotoxic groups. In Biological Characterization of Human Tumors","volume":"375","author":"K\u00f6nyves I","year":"1975","journal-title":"Excerpta Medica Int Cong Ser"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-3030-1_94"},{"key":"e_1_2_1_32_2","volume-title":"Cytotoxic Estrogens in Hormone Receptive Tumors","author":"Raus J","year":"1980"},{"issue":"1","key":"e_1_2_1_33_2","first-page":"28","article-title":"The distribution of radioactivity after administration of labelled estramustine phosphate (Estracyt), estradiol\u201017\u2010phosphate and estradiol to rats","volume":"35","author":"Plym Forshell G","year":"1974","journal-title":"Acta Pharmacol Toxicol"},{"key":"e_1_2_1_34_2","first-page":"177","article-title":"Studies on the conversion of estradiol linked to a cytostatic agent (Estracyt) in various rat tissues","volume":"82","author":"H\u00f8isaeter P\u00c5","year":"1976","journal-title":"Acta Endocrinol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.7.3149"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189261"},{"key":"e_1_2_1_37_2","unstructured":"GunnarssonP\u2010O: Personal communication 1983."},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1979.tb02287.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00256611"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)54057-4"},{"key":"e_1_2_1_41_2","first-page":"253","volume-title":"Prostate Cancer","author":"Edsmyr F","year":"1982"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.2990050106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.2990050106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T12:46:26Z","timestamp":1697805986000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.2990050106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1984,1]]}},"alternative-id":["10.1002\/pros.2990050106"],"URL":"https:\/\/doi.org\/10.1002\/pros.2990050106","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,1]]}}}